Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Notice of results and shareholder update

30th Aug 2012 11:14

RNS Number : 1000L
Allergy Therapeutics PLC
30 August 2012
 



Allergy Therapeutics plc

("Allergy Therapeutics" or the "Company")

 

Notice of results and shareholder update

 

Allergy Therapeutics plc (AIM: "AGY" or the "Company"), the fully integrated specialty pharmaceutical company specialising in allergy vaccines, will announce its Preliminary Results for the year ended 30 June 2012 on Monday 17 September 2012.

 

The Company also announces that CFR Pharmaceutical SA ("CFR"), a company associated with the Weinstein family and the largest shareholder in Allergy Therapeutics, will release its interim results for the period ended 30 June 2012 on the 30 August 2012. In order that CFR can comply with its reporting requirements Allergy Therapeutics has made the following unaudited financial information below available to CFR.

 

Balance Sheet as at 31 March 2012

 

£ '000

Total Non-Current Assets

15,085

Total Current Assets

17,207

Total Current Liabilities

(19,027)

Total Non-Current Liabilities

(4,316)

Total Equity

8,949

 

Consolidated Income Statement for the 6 months ended 31 March 2012

 

£'000

Revenue

27,595

Profit after tax for the period

6,777

 

Items have the same meaning as disclosed in Allergy Therapeutics plc's accounts for the year ended 30 June 2011.

 

-Ends-

 

For further information

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Ian Postlethwaite, Finance Director

www.allergytherapeutics.com

Nomura Code Securities

+44 (0) 207 776 1200

Juliet Thompson/ Clare Terlouw

FTI Consulting

+44 (0) 207 831 3113

Simon Conway/ Susan Stuart

 

Notes to editors

 

About Allergy Therapeutics

Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business achieving sales in the prior financial year of £42 million mainly in Europe through its own sales and marketing infrastructure and further afield through distributors. The Company is expanding its infrastructure into the Emerging Markets.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCPMMMTMBBJBJT

Related Shares:

Allergy Thera.
FTSE 100 Latest
Value8,596.28
Change53.72